Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced a strategic refocusing of its research and development portfolio following the expiration and termination of its option and license arrangements with PinCell S.r.l. related to PC111, which ended on August 31. The company emphasized that this decision was not driven by any new negative scientific findings regarding PC111. Instead, it allows Scinai to concentrate its R&D resources on its NanoAb platform while preserving capital and management capacity for its contract development and manufacturing organization (CDMO) business, which is already generating revenue.
This refocusing comes at a critical time as the company aims to streamline operations and prioritize high-potential programs. Scinai is advancing two IL-17 programs within its NanoAb platform, including an intradermal psoriasis program. Notably, approximately €12 million in grant financing is under evaluation in Poland to support this initiative. The NanoAb platform, which leverages single-domain antibodies, is considered a key driver for future growth, offering potential advantages in manufacturing and delivery compared to conventional antibodies.
Financially, the company reported approximately $3.1 million in committed CDMO customer orders as of August 16. It continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue recognition, and additional business opportunities. The CDMO business, operated through Scinai Biopharma Services Ltd., provides development and manufacturing services to biotechnology and pharmaceutical companies from facilities in Jerusalem and Yavne, Israel.
The strategic pivot underscores Scinai's commitment to enhancing shareholder value by focusing on areas with near-term revenue potential and scientific promise. By terminating the PinCell agreement, the company avoids potential future financial obligations and can allocate resources more efficiently. This move is likely to be viewed positively by investors as it demonstrates disciplined capital management and a clear strategic direction.
For more details on this announcement, please refer to the full press release at https://ibn.fm/nnx0Z. Additionally, the latest news and updates regarding Scinai are available in the company's newsroom at https://ibn.fm/SCNI.
